Dr. Ruan on Stratifying Risk in MCL

Jia Ruan, MD, PhD, discusses stratifying risk in mantle cell lymphoma.

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses stratifying risk in mantle cell lymphoma (MCL).

MCL is a rare subtype of non-Hodgkin lymphoma that accounts for approximately 5% to 8% of all patients with B-cell non-Hodgkin lymphoma, says Ruan.

Moreover, MCL is associated with unique clinical and pathological features, including translocation 11;14 and cyclin D1 expression, explains Ruan.

Through the use of stratification tools that examine these features, such as the Mantle Cell Lymphoma International Prognostic Index, the risk associated with a patient’s disease can be determined, concludes Ruan.

Related Videos
Paolo Tarantino, MD
Aditya Bardia, MD, MPH, FASCO
Giuseppe Curigliano, MD, PhD, director, Early Drug Development Division, co-chair, Experimental Therapeutics Program, the European Institute of Oncology
Mina Lobbous, MD, MPH
Noa Biran, MD
Andrew Hantel, MD
Peter Forsyth, MD
Jakub Svoboda, MD
Joaquim Bellmunt, MD, PhD
María-Victoria Mateos, MD, PhD